Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies

References

• MacdonaldJBMacdonaldBGolitzLELoRussoPSekulicACutaneous adverse effects of targeted therapies – part I: inhibitors of the cellular membraneJ Am Acad Dermatol201572220322025592338
   PubMed Web of Science ®Google Scholar
• RosenACBalagulaYRaischDWLife-threatening dermatologic adverse events in oncologyAnticancer Drugs201425222523424108082
   PubMed Web of Science ®Google Scholar
• PhillipsEJChungWHMockenhauptMRoujeauJCMallalSADrug hypersensitivity: pharmacogenetics and clinical syndromesJ Allergy Clin Immunol20111273 SupplS60S6621354501
   PubMed Web of Science ®Google Scholar
• RoujeauJCSternRSSevere adverse cutaneous reactions to drugsN Engl J Med199433119127212857794310
   PubMed Web of Science ®Google Scholar
• RoujeauJCGuillaumeJCFabreJPPensoDFléchetMLGirreJPToxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981–1985Arch Dermatol1990126137422134982
   PubMedGoogle Scholar
• LinWLLinWCYangJYFatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancerJ Clin Oncol200826162779278018509187
   PubMed Web of Science ®Google Scholar
• SchwartzRAMcDonoughPHLeeBWToxic epidermal necrolysis – part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatmentJ Am Acad Dermatol2013692187e1e1620320423866879
   PubMed Web of Science ®Google Scholar
• KardaunSHSidoroffAValeyrie-AllanoreLVariability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?Br J Dermatol2007156360961117300272
   PubMed Web of Science ®Google Scholar
• CacoubPMusettePDescampsVThe DRESS syndrome: a literature reviewAm J Med2011124758859721592453
   PubMed Web of Science ®Google Scholar
• KardaunSHSekulaPValeyrie-AllanoreLDrug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction: results from the prospective RegiSCAR studyBr J Dermatol201316951071108023855313
   PubMed Web of Science ®Google Scholar
• SidoroffADunantAViboudCRisk factors for acute generalized exanthematous pustulosis (AGEP): results of a multinational case-control study (EuroSCAR)Br J Dermatol2007157598999617854366
   PubMed Web of Science ®Google Scholar
• GeyAMilpiedBDutriauxCSevere cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?J Eur Acad Dermatol Venereol201630117817925175726
   PubMed Web of Science ®Google Scholar
• MinorDRRodvienRKashani-SabetMSuccessful desensitization in a case of Stevens-Johnson syndrome due to vemurafenibMelanoma Res201222541041122828249
   PubMed Web of Science ®Google Scholar
• BellonTLermaVGonzalez-ValleOHerradaCGde AbajoFJVemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compoundsBr J Dermatol2016174362162426412570
   PubMed Web of Science ®Google Scholar
• DidonaDPaolinoGGarcovichSCaroRDDidonaBSuccessful use of etanercept in a case of toxic epidermal necrolysis induced by rituximabJ Eur Acad Dermatol Venereol20163010e83e8426428058
   PubMed Web of Science ®Google Scholar
• VivarKLDeschaineMMessinaJEpidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapyJ Cutan Pathol201744438138428000240
   PubMed Web of Science ®Google Scholar
• Bastuji-GarinSFouchardNBertocchiMRoujeauJCRevuzJWolkensteinPSCORTEN: a severity-of-illness score for toxic epidermal necrolysisJ Invest Dermatol2000115214915310951229
   PubMed Web of Science ®Google Scholar
• GueganSBastuji-GarinSPoszepczynska-GuigneERoujeauJCRevuzJPerformance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysisJ Invest Dermatol2006126227227616374461
   PubMed Web of Science ®Google Scholar
• WuJLeeYYSuSCStevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignanciesBr J Dermatol201517351224123126218033
   PubMed Web of Science ®Google Scholar
• LiuHBWuYLvTFSkin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisPLoS One201381e5512823383079
   PubMed Web of Science ®Google Scholar
• SanlorenzoMVujicIDaudAPembrolizumab cutaneous adverse events and their association with disease progressionJAMA Dermatol2015151111206121226222619
   PubMed Web of Science ®Google Scholar
• Freeman-KellerMKimYCroninHRichardsAGibneyGWeberJSNivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomesClin Cancer Res201622488689426446948
   PubMed Web of Science ®Google Scholar
• SeshacharyuluPPonnusamyMPHaridasDJainMGantiAKBatraSKTargeting the EGFR signaling pathway in cancer therapyExpert Opin Ther Targets2012161153122239438
   PubMed Web of Science ®Google Scholar
• YewaleCBaradiaDVhoraIPatilSMisraAEpidermal growth factor receptor targeting in cancer: a review of trends and strategiesBiomaterials201334348690870723953842
   PubMed Web of Science ®Google Scholar
• LacoutureMEAnadkatMJBensadounRJClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupport Care Cancer20111981079109521630130
   PubMed Web of Science ®Google Scholar
• WnorowskiAMde SouzaAChachouaACohenDEThe management of EGFR inhibitor adverse events: a case series and treatment paradigmInt J Dermatol201251222323222250636
   PubMed Web of Science ®Google Scholar
• LiqueteEAliSKammoRAcute Generalized exanthematous pustulosis induced by erlotinib (Tarceva) with superimposed Staphylococcus aureus skin infection in a pancreatic cancer patient: a case reportCase Rep Oncol20125225325922712013
   PubMedGoogle Scholar
• Bastuji-GarinSRzanyBSternRSShearNHNaldiLRoujeauJCClinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiformeArch Dermatol1993129192968420497
   PubMedGoogle Scholar
• OtsukaTTanakaAAzukizawaHSuccessful treatment with gefitinib after Stevens–Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lungInt Cancer Conf J2017613841
   PubMedGoogle Scholar
• HondaYHattoriYKatsuraSStevens-Johnson syndrome-like erosive dermatitis possibly related to afatinibEur J Dermatol201626441341427212422
   PubMed Web of Science ®Google Scholar
• ChungWHHungSIYangJYGranulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysisNat Med200814121343135019029983
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• CasaliPGLe CesneAVelascoAPImatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): the EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trialJ Clin Oncol20133115 Suppl10500
   Google Scholar
• LeonettiFStefanachiANicolottiOBCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profileCurr Med Chem201118192943295921651486
   PubMed Web of Science ®Google Scholar
• IqbalNIqbalNImatinib: a breakthrough of targeted therapy in cancerChemother Res Pract2014201435702724963404
   PubMedGoogle Scholar
• ValeyrieLBastuji-GarinSRevuzJAdverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patientsJ Am Acad Dermatol200348220120612582389
   PubMed Web of Science ®Google Scholar
• BrouardMSauratJHCutaneous reactions to STI571N Engl J Med2001345861861911529225
   PubMed Web of Science ®Google Scholar
• WhiteKDChungWHHungSIMallalSPhillipsEJEvolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug responseJ Allergy Clin Immunol2015136221923426254049
   PubMed Web of Science ®Google Scholar
• DuongTAValeyrie-AllanoreLWolkensteinPChosidowOSevere cutaneous adverse reactions to drugsLancet2017390101061996201128476287
   PubMed Web of Science ®Google Scholar
• MahapatraMMishraPKumarRImatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower doseAnn Hematol200786753753817287945
   PubMed Web of Science ®Google Scholar
• PavithranKThomasMImatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower doseIndian J Dermatol Venereol Leprol200571428828916394445
   PubMedGoogle Scholar
• Sanchez-GonzalezBPascual-RamirezJCFernandez-AbellanPBelinchon-RomeroIRivasCVegara-AguileraGSevere skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemiaBlood200310162446
   PubMed Web of Science ®Google Scholar
• RuleSAO’BrienSGCrossmanLCManaging cutaneous reactions to imatinib therapyBlood200210093434343512412577
   PubMed Web of Science ®Google Scholar
• KumarMMandalPKDolaiTKBhattacharryaMImatinib causing drug rash with eosinophilia and systemic symptoms: a rare cutaneous reactionIndian Dermatol Online J20145Suppl 2S120S12225593801
   PubMedGoogle Scholar
• GotinkKJVerheulHMAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Angiogenesis201013111420012482
   PubMed Web of Science ®Google Scholar
• JeongWDoroshowJHKummarSUnited States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignanciesCurr Probl Cancer201337311014423972982
   PubMed Web of Science ®Google Scholar
• IshakRSAadSAKyeiAFarhatFSCutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitorsCrit Rev Oncol Hematol201490215216424355408
   PubMed Web of Science ®Google Scholar
• BillemontBBareteSRixeOScrotal cutaneous side effects of sunitinibN Engl J Med2008359997597618753659
   PubMedGoogle Scholar
• ChanprapaphKRutninSVachiramonVMultikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and managementAm J Clin Dermatol201617438740227221667
   PubMed Web of Science ®Google Scholar
• GuptaVRaoAGuptaSScrotal cutaneous toxicity: an uncommon but important side-effect of sunitinibJ Eur Acad Dermatol Venereol201630113213325060046
   PubMed Web of Science ®Google Scholar
• ChoiMKWooHYHeoJToxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinomaAnn Dermatol201123Suppl 3S404S40722346290
   PubMedGoogle Scholar
• BlanchetBBillemontBBareteSToxicity of sorafenib: clinical and molecular aspectsExpert Opin Drug Saf20109227528720078249
   PubMed Web of Science ®Google Scholar
• YehCNChungWHSuSCFas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reactionJ Invest Dermatol2014134112768277524802849
   PubMed Web of Science ®Google Scholar
• ZimmermanEIGibsonAAHuSMultikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell deathCancer Res201676111712626677977
   PubMed Web of Science ®Google Scholar
• IkedaMFujitaTAmohYMiiSMatsumotoKIwamuraMStevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinomaUrol Int201391448248323969404
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood19948324354457506951
   PubMed Web of Science ®Google Scholar
• EdwardsJCCambridgeGB-cell targeting in rheumatoid arthritis and other autoimmune diseasesNat Rev Immunol20066539440316622478
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LopezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol1998168282528339704735
   PubMed Web of Science ®Google Scholar
• HenningJSFirozBFRituxan is not associated with Stevens Johnson SyndromeAnn Oncol20112261463146421525404
   PubMed Web of Science ®Google Scholar
• AnhaltGJKimSCStanleyJRParaneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasiaN Engl J Med199032325172917352247105
   PubMed Web of Science ®Google Scholar
• JolyPRichardCGilbertDSensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigusJ Am Acad Dermatol200043461962611004616
   PubMed Web of Science ®Google Scholar
• HornTDAnhaltGJHistologic features of paraneoplastic pemphigusArch Dermatol19921288109110951497365
   PubMedGoogle Scholar
• FallonMJHeckJNFatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapyJ Oncol Pharm Pract201521538839225005569
   PubMed Web of Science ®Google Scholar
• KarouliaZGavathiotisEPoulikakosPINew perspectives for targeting RAF kinase in human cancerNat Rev Cancer2017171167669128984291
   PubMed Web of Science ®Google Scholar
• LacoutureMEDuvicMHauschildAAnalysis of dermatologic events in vemurafenib-treated patients with melanomaOncologist201318331432223457002
   PubMed Web of Science ®Google Scholar
• SinhaRLarkinJGoreMFearfieldLCutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentationsBr J Dermatol201517341024103126109403
   PubMed Web of Science ®Google Scholar
• de GolianEKwongBYSwetterSMPuglieseSBCutaneous complications of targeted melanoma therapyCurr Treat Options Oncol201617115727645330
   PubMed Web of Science ®Google Scholar
• ArenbergerovaMMrazovaIHorazdovskyJSticovaEFialovaAArenbergerPToxic epidermal necrolysis induced by vemurafenib after nivolumab failureJ Eur Acad Dermatol Venereol2017315e253e25427739125
   PubMed Web of Science ®Google Scholar
• HardingJJPulitzerMChapmanPBVemurafenib sensitivity skin reaction after ipilimumabN Engl J Med2012366986686822375995
   PubMed Web of Science ®Google Scholar
• JeudyGDalac-RatSBonniaudBSuccessful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysisBr J Dermatol201517251454145525384395
   PubMed Web of Science ®Google Scholar
• WolchokJDChiarion-SileniVGonzalezROverall survival with combined nivolumab and ipilimumab in advanced melanomaN Engl J Med2017377141345135628889792
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• CurryJLTetzlaffMTNagarajanPDiverse types of dermatologic toxicities from immune checkpoint blockade therapyJ Cutan Pathol201744215817627859479
   PubMed Web of Science ®Google Scholar
• PolderKWangCDuvicMToxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphomaLeuk Lymphoma200546121807181116263585
   PubMed Web of Science ®Google Scholar
• WienerJSTuckerJAJrWaltherPJInterleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysisSouth Med J19928566566591534937
   PubMed Web of Science ®Google Scholar
• HuertaAATorderaPCercosACYusteALLopez-TenderoPReynesGToxic epidermal necrolysis associated with interleukin-2Ann Pharmacother2002367–81171117412086549
   PubMed Web of Science ®Google Scholar
• NayarNBriscoeKFernandez-PenasPToxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanomaJ Immunother201639314915226938948
   PubMed Web of Science ®Google Scholar
• GoldingerSMStiegerPMeierBCytotoxic cutaneous adverse drug reactions during anti-PD-1 therapyClin Cancer Res201622164023402926957557
   PubMed Web of Science ®Google Scholar
• LinikerEMenziesAMKongBYActivity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanomaOncoimmunology201659e121478827757312
   PubMed Web of Science ®Google Scholar
• DikaERavaioliGMFantiPACutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective studyEur J Dermatol201727326627028524050
   PubMed Web of Science ®Google Scholar
• HwangSJCarlosGWakadeDSharmaRFernandez-PenasPIpilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanomaMelanoma Res201626441742027031538
   PubMed Web of Science ®Google Scholar
• VoskensCJGoldingerSMLoquaiCThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkPLoS One201381e5374523341990
   PubMed Web of Science ®Google Scholar
• SawSLeeHYNgQSPembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patientsEur J Cancer20178123723928438440
   PubMed Web of Science ®Google Scholar
• Le NaourSPeuvrelLSaint-JeanMDrenoBQuereuxGThree new cases of bullous pemphigoid during anti-PD-1 antibody therapyJ Eur Acad Dermatol Venereol2018323e104e10628865162
   PubMed Web of Science ®Google Scholar
• MacdonaldJBMacdonaldBGolitzLELoRussoPSekulicACutaneous adverse effects of targeted therapies – part II: inhibitors of intracellular molecular signaling pathwaysJ Am Acad Dermatol201572222123825592339
   PubMed Web of Science ®Google Scholar
• SaidiWLahouelILaarifMAounallahAA new case of imatinib-induced drug reaction with eosinophilia and systemic symptomsIndian J Dermatol Venereol Leprol201783222422628164890
   PubMed Web of Science ®Google Scholar
• HsiaoLTChungHMLinJTStevens-Johnson syndrome after treatment with STI571: a case reportBr J Haematol2002117362062212028031
   PubMed Web of Science ®Google Scholar
• BrouardMCPrinsCMach-PascualSSauratJHAcute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemiaDermatology20012031575911549802
   PubMed Web of Science ®Google Scholar
• ScottADLeeMKubbaFChuAAcute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemiaClin Exp Dermatol201540892692725266712
   PubMed Web of Science ®Google Scholar
• ShihHCHsiaoYPWuMFYangJHGefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancerBr J Dermatol200615551101110217034565
   PubMed Web of Science ®Google Scholar
• SidoroffAHalevySBavinckJNVaillantLRoujeauJCAcute generalized exanthematous pustulosis (AGEP): a clinical reaction patternJ Cutan Pathol200128311311911168761
   PubMed Web of Science ®Google Scholar
• RoeEMuretMPMarcuelloECapdevilaJPallaresCAlomarADescription and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patientsJ Am Acad Dermatol200655342943716908348
   PubMed Web of Science ®Google Scholar
• BrodellLAHepperDLindAGruAAAnadkatMJHistopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitorsJ Cutan Pathol2013401086587023941617
   PubMed Web of Science ®Google Scholar
• KardaunSHKuiperHFidlerVJonkmanMFThe histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasisJ Cutan Pathol201037121220122920738458
   PubMed Web of Science ®Google Scholar
• HalevySKardaunSHDavidoviciBWechslerJThe spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 casesBr J Dermatol201016361245125220698849
   PubMed Web of Science ®Google Scholar
• LeeYYChungWHAcute generalized exanthematous pustulosis: a retrospective study of 51 cases in TaiwanDermatol Sin2014323137140
   Web of Science ®Google Scholar
• HotzCValeyrie-AllanoreLHaddadCSystemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patientsBr J Dermatol201316961223123223855377
   PubMed Web of Science ®Google Scholar
• NaranjoCABustoUSellersEMA method for estimating the probability of adverse drug reactionsClin Pharmacol Ther19813022392457249508
   PubMed Web of Science ®Google Scholar
• SassolasBHaddadCMockenhauptMALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysisClin Pharmacol Ther2010881606820375998
   PubMed Web of Science ®Google Scholar
• GuthrieBMakubateBHernandez-SantiagoVDreischulteTThe rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010BMC Med2015137425889849
   PubMed Web of Science ®Google Scholar
• HengYKLimYLCutaneous adverse drug reactions in the elderlyCurr Opin Allergy Clin Immunol201515430030726110679
   PubMed Web of Science ®Google Scholar
• Urosevic-MaiwaldMHarrTFrenchLEDummerRStevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancerInt J Dermatol201251786486722715836
   PubMed Web of Science ®Google Scholar
• ImafukuKYoshinoKIshiwataKSevere rash associated with vemurafenib administration following nivolumab therapyJ Eur Acad Dermatol Venereol20163010e84e8626372833
   PubMed Web of Science ®Google Scholar
• PichlerWJTilchJThe lymphocyte transformation test in the diagnosis of drug hypersensitivityAllergy200459880982015230812
   PubMed Web of Science ®Google Scholar
• KanoYHiraharaKMitsuyamaYTakahashiRShioharaTUtility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruptionAllergy200762121439144417983378
   PubMed Web of Science ®Google Scholar
• Nagao-DiasATTeixeiraFMCoelhoHLDiagnosing immune-mediated reactions to drugsAllergol Immunopathol (Madr)20093729810419445867
   PubMed Web of Science ®Google Scholar
• BarbaudAColletEMilpiedBA multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactionsBr J Dermatol2013168355556223136927
   PubMed Web of Science ®Google Scholar
• DoeschJDebusDMeyerCAfatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patientLung Cancer201695353827040849
   PubMed Web of Science ®Google Scholar
• LeeSSChuPYToxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancerAm J Otolaryngol201031428829020015761
   PubMed Web of Science ®Google Scholar
• PantanoFSillettaMIovienoAStevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitunumab [sic]Int J Colorectal Dis200924101247124819225787
   PubMed Web of Science ®Google Scholar
• JackmanDMCioffrediLAJacobsLA phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerOncotarget2015664527453625784657
   PubMedGoogle Scholar
• HuangJJMaSXHouXToxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancerChin J Cancer2015342949825418188
   PubMedGoogle Scholar
• YoonJOhCWKimCYStevens-Johnson syndrome induced by vandetanibAnn Dermatol201123Suppl 3S343S34522346274
   PubMed Web of Science ®Google Scholar
• LadizinskiBSankeyCA topical matter: toxic epidermal necrolysisAm J Med20141271093193224950488
   PubMed Web of Science ®Google Scholar
• BoisEHolleLMFarooqULate onset imatinib-induced Stevens-Johnson syndromeJ Oncol Pharm Pract201420647647824399835
   PubMed Web of Science ®Google Scholar
• JhaPHimanshuDJainNSinghAKImatinib-induced Stevens-Johnsons syndromeBMJ Case Rep20132013
   PubMedGoogle Scholar
• NakamotoKNagaharaHNodaEThree cases of giant rectal gastrointestinal stromal tumorGan To Kagaku Ryoho2011381219841986 Japanese22202260
   PubMedGoogle Scholar
• VidalDPuigLSuredaAAlomarASti571-induced Stevens-Johnson SyndromeBr J Haematol2002119127427512358937
   PubMed Web of Science ®Google Scholar
• SchaichMSchäkelKIllmerTEhningerGBornhauserMSevere epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantationAnn Hematol200382530330412707720
   PubMed Web of Science ®Google Scholar
• HsiehHJChanALLinSJStevens-Johnson syndrome induced by combination of imatinib and allopurinolChemotherapy200955419719919439939
   PubMed Web of Science ®Google Scholar
• SeverinoGChillottiCde LisaRdel ZompoMArdauRAdverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumorsAnn Pharmacother200539116216415546944
   PubMed Web of Science ®Google Scholar
• GoldmanJDuval-ModesteABLambertAImatinib-induced DRESSAnn Dermatol Venereol20081355393396 French18457727
   PubMed Web of Science ®Google Scholar
• Le NouailPViseuxVChabyGBilletADenoeuxJPLokCDrug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapyAnn Dermatol Venereol20061338–9 Pt 1686688 French17053739
   PubMed Web of Science ®Google Scholar
• SchwarzMKreuzerKABaskaynakGDorkenBle CoutrePImatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemiaEur J Haematol200269425425612431246
   PubMed Web of Science ®Google Scholar
• SohnKHOhSYLimKWKimMYLeeSYKangHRSorafenib induces delayed-onset cutaneous hypersensitivity: a case seriesAllergy Asthma Immunol Res20157330430725749785
   PubMed Web of Science ®Google Scholar
• Alegre-SanchezAde Perosanz-LoboDPinilla-PagnonIMunoz-ZatoESorafenib-induced acute generalized exanthematous pustulosis: an increasing association?Actas Dermosifiliogr2017108659960128262110
   PubMedGoogle Scholar
• LiangCPYangCSShenJLChenYJSorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinomaBr J Dermatol2011165244344521495998
   PubMed Web of Science ®Google Scholar
• PretelMInarrairaeguiMLeraJMAguadoLIdoateMAAcute generalized exanthematous pustulosis induced by sorafenibJAMA Dermatol2014150666466624671701
   PubMed Web of Science ®Google Scholar
• FangBSongYMaJZhaoRCSevere epidermal necrolysis after bortezomib treatment for multiple myelomaActa Haematol20071182656717505132
   PubMed Web of Science ®Google Scholar
• CastanedaCPBrandenburgNABwireRBurtonGHZeldisJBErythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patientsJ Clin Oncol200927115615719047275
   PubMed Web of Science ®Google Scholar
• HattoriNAdachiDNakashimaHSaitoBNakamakiTTomoyasuSDrug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myelomaLeuk Res200933457457718838167
   PubMed Web of Science ®Google Scholar
• LowndesSDarbyAMeadGListerAStevens-Johnson syndrome after treatment with rituximabAnn Oncol200213121948195012453865
   PubMed Web of Science ®Google Scholar
• PariseLKahleJSchlaakMMauchCKurschatPReply to Rituxan is not associated with Stevens-Johnson syndromeAnn Oncol2012233807
   PubMed Web of Science ®Google Scholar
• ForanJMGuptaRKCunninghamDA UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular responseBr J Haematol20001091818810848785
   PubMed Web of Science ®Google Scholar
• NewlandAMLiJXWascoLEAzizMTLoweDKBrentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugatePharmacotherapy20133319310423307550
   PubMed Web of Science ®Google Scholar
• del PrincipeMISconocchiaGBuccisanoFExtensive toxic epidermal necrolysis following brentuximab vedotin administrationAnn Hematol201594235535624981690
   PubMed Web of Science ®Google Scholar
• KiliçSOzkayaEBaykalCVatanseverSVemurafenib-induced toxic epidermal necrolysis: is it an emerging side effect of the drug?J Eur Acad Dermatol Venereol2017318e354e35528150343
   PubMed Web of Science ®Google Scholar
• LaprestaADotorAGonzalez-HerradaCToxic epidermal necrolysis induced by vemurafenibActas Dermosifiliogr2015106868268326051238
   PubMedGoogle Scholar
• WantzMSpanoudi-KITrimiILasekALebasDQuinchonJFModianoPVemurafenib-induced toxic epidermal necrolysisAnn Dermatol Venereol20141413215218 French24635957
   PubMed Web of Science ®Google Scholar
• SinhaRLecamwasamKPurshouseKReedJMiddletonMRFearfieldLToxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanomaBr J Dermatol2014170499799924359127
   PubMed Web of Science ®Google Scholar
• MunchMPeuvrelLBrocardAEarly-onset vemurafenib-induced DRESS syndromeDermatology2016232112612826418832
   PubMed Web of Science ®Google Scholar
• WenkKSPichardDCNasabzadehTJangSVennaSSVemurafenib-induced DRESSJAMA Dermatol2013149101242124323986488
   PubMed Web of Science ®Google Scholar
• PathriaMMundiJTrufantJA case of Stevens-Johnson syndrome in a patient on ipilimumabInt J Case Rep Imag201675300302
   Google Scholar